Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer
about
Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effectsVitamin C in human health and disease is still a mystery? An overviewVitamin C for preventing and treating tetanusVitamin C for preventing and treating tetanusPharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues.Intravenously administered vitamin C as cancer therapy: three casesMegavitamin and megamineral therapy in childhood. Nutrition Committee, Canadian Paediatric SocietySupplemental ascorbate in the supportive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancerPharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in miceVitamin C: update on physiology and pharmacologyAscorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivoAscorbate depletion: a critical step in nickel carcinogenesis?Treatment of Pancreatic Cancer with Pharmacological AscorbateAscorbate as a co-factor for fe- and 2-oxoglutarate dependent dioxygenases: physiological activity in tumor growth and progressionReview: When is an antioxidant not an antioxidant? A review of novel actions and reactions of vitamin CNew insights into the physiology and pharmacology of vitamin CCytotoxicity of ascorbate, lipoic acid, and other antioxidants in hollow fibre in vitro tumoursEvaluating interventions for Ebola: The need for randomized trialsHigh-Dose Intravenous Vitamin C Treatment of a Child with Neurofibromatosis Type 1 and Optic Pathway Glioma: A Case Report.Mechanisms of ascorbate-induced cytotoxicity in pancreatic cancerData acquisition for assessment of medical technology: methods other than technical trials.Biostatistical analysis of mortality data for cohorts of cancer patients.NADH autofluorescence, a new metabolic biomarker for cancer stem cells: Identification of Vitamin C and CAPE as natural products targeting "stemness".The prospects of vitamin C in cancer therapyThe effectiveness of inpatient rehabilitation in the acute postoperative phase of care after transtibial or transfemoral amputation: study of an integrated health care delivery system.Nutritional aspects of ascorbic acid: uses and abusesPhase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.Antioxidants and Other Micronutrients in Complementary Oncology.Diet and cancer--should we change what we eat?Molecular expression and functional activity of vitamin C specific transport system (SVCT2) in human breast cancer cells.Natural resistance to ascorbic acid induced oxidative stress is mainly mediated by catalase activity in human cancer cells and catalase-silencing sensitizes to oxidative stress.Criteria for the validity of clinical trials of treatments of cohorts of cancer patients based on the Hardin Jones principleOrthomolecular oncology review: ascorbic acid and cancer 25 years later.Review of high-dose intravenous vitamin C as an anticancer agent.Is there a role for oral or intravenous ascorbate (vitamin C) in treating patients with cancer? A systematic review.The use of antioxidants with first-line chemotherapy in two cases of ovarian cancer.Vitamin C and cancer revisitedHigh concentrations of L-ascorbic acid specifically inhibit the growth of human leukemic cells via downregulation of HIF-1α transcription.Intravenous ascorbic acid to prevent and treat cancer-associated sepsis?Vitamin C: a concentration-function approach yields pharmacology and therapeutic discoveries.
P2860
Q21136326-0C53DA66-DE0C-4FF6-8093-90F154C815A3Q21245913-2E7FB93E-8766-41D4-BAE8-6373DC588986Q24202470-29A8D696-98D0-4302-ADF9-0E1B1A55FC1EQ24243060-1DAA15B1-6996-4FBA-997F-6B477992FEF6Q24531307-C5976A61-674C-447E-ABD9-426373598E62Q24540524-C6A13715-41B7-4728-AA34-F75259B6B58CQ24545481-512B0551-D84E-4888-8632-625CBAA173B9Q24616530-2491F4AA-1F64-4898-A26E-3C49B46A1169Q24644317-B99EBAAE-7FF6-45EF-B7B8-1DB85E7A26E7Q24654791-AD4AEA4A-1B60-4B44-972E-4FC3CF91C788Q24678072-0BD6494A-914F-4ABA-8626-39516206A667Q24812869-DCC00CA7-5E69-4670-8914-A87B41AE7D11Q26800853-FFB2439F-8678-4728-B457-EE4731D37E1EQ26822640-72837E83-3A24-4C1C-B82D-311C24019EEAQ28263084-B645E6EC-5F14-4904-AAE1-3E491E4EAB8CQ28357822-B4872503-7F90-4A21-B493-B58B9BFDE9CAQ28366046-3D48843D-7E2E-4CB1-909C-B0D43D06EA95Q28388002-2E2E2BD3-A191-40BA-91BC-D1ABD37F0CAAQ30370309-812CE5FC-AC04-4CDC-A96D-8004FCC1CDC7Q30492805-906DE7C4-7991-4C95-BF9F-5BAF07302968Q30575337-11506CD0-416E-42D3-828F-1F259B57F0A4Q31105892-0A69CE67-2CBB-470E-90CA-4F336628881EQ33591293-0064AE36-B871-4EE6-BCE1-0372BB5B93B0Q33631944-B7DE5C87-9E2E-44AD-9582-523FF97FF3A0Q33894516-C5474089-9F9B-4D20-B1BA-F5067FA6B7FBQ34108998-C4D7774B-E0DB-4D6E-96C5-B0156D4ADFC2Q34137350-5AB2E9F8-FF4C-495B-A842-0FE5AF724B29Q34140158-80848E77-E2E6-47F3-A925-CA21611E8D0FQ34195094-6F6DF63E-C19F-4A8D-8F23-E0E2EB3C6760Q34243867-6265D99C-2ABA-4552-BEDC-2EF03FE6D0DCQ34253716-C41DBC8B-18E8-4019-BC88-C9E4A92025EEQ34302471-237032B0-69C0-4384-8DC6-FF783F7D5D4FQ34391627-AD7CD1E9-C4AA-412D-8B77-1694CADCB017Q34406887-745B5635-2806-41F5-BCB3-20DA127908DBQ34458788-2750824D-A17B-4830-AA49-D54EB73FF8B1Q34532488-A7CF6594-EB0F-4F03-964C-72B58DE7DED0Q34595214-3C2E3C10-4249-4955-BB63-BBD5B7BA406BQ34693392-A8B722A0-E411-4175-B972-08EC6AF97398Q34704572-D66EAAE7-3D1C-47A5-B95A-2733B52E0410Q34729895-5CA210C1-8351-45F9-A176-4048BABE0F4F
P2860
Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer
description
1976 nî lūn-bûn
@nan
1976 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1976 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1976年の論文
@ja
1976年論文
@yue
1976年論文
@zh-hant
1976年論文
@zh-hk
1976年論文
@zh-mo
1976年論文
@zh-tw
1976年论文
@wuu
name
Supplemental ascorbate in the ...... times in terminal human cancer
@ast
Supplemental ascorbate in the ...... times in terminal human cancer
@en
Supplemental ascorbate in the ...... times in terminal human cancer
@nl
type
label
Supplemental ascorbate in the ...... times in terminal human cancer
@ast
Supplemental ascorbate in the ...... times in terminal human cancer
@en
Supplemental ascorbate in the ...... times in terminal human cancer
@nl
prefLabel
Supplemental ascorbate in the ...... times in terminal human cancer
@ast
Supplemental ascorbate in the ...... times in terminal human cancer
@en
Supplemental ascorbate in the ...... times in terminal human cancer
@nl
P2860
P3181
P356
P1476
Supplemental ascorbate in the ...... times in terminal human cancer
@en
P2093
P2860
P304
P3181
P356
10.1073/PNAS.73.10.3685
P407
P577
1976-10-01T00:00:00Z